评价司美格鲁肽注射液与原研司美格鲁肽注射液在中国肥胖受试者中安全性和有效性的多中心、随机、开放、平行对照的III期临床研究
[Translation] A multicenter, randomized, open, parallel-controlled phase III clinical study to evaluate the safety and efficacy of semaglutide injection and original semaglutide injection in obese Chinese subjects
在减少饮食热量摄入和增加体力活动基础上,评价采用试验药物司美格鲁肽注射液与对照药品原研司美格鲁肽注射液治疗44周后,在中国肥胖非糖尿病受试者中减重的等效性。
[Translation] To evaluate the equivalence of weight loss between the investigational drug semaglutide injection and the control drug original semaglutide injection in Chinese obese non-diabetic subjects after 44 weeks of treatment, based on reduced dietary calorie intake and increased physical activity.
100 Clinical Results associated with Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co
0 Patents (Medical) associated with Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co
100 Deals associated with Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co
100 Translational Medicine associated with Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co